Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) and Mitsui & Co. (OTCMKTS:MITSY – Get Free Report) are both industrials companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Analyst Ratings
This is a breakdown of recent ratings for Capstone Therapeutics and Mitsui & Co., as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capstone Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Mitsui & Co. | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares Capstone Therapeutics and Mitsui & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capstone Therapeutics | -36.51% | -144.43% | -40.48% |
| Mitsui & Co. | 6.22% | 10.67% | 4.76% |
Institutional & Insider Ownership
Volatility and Risk
Capstone Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the S&P 500. Comparatively, Mitsui & Co. has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.
Valuation and Earnings
This table compares Capstone Therapeutics and Mitsui & Co.”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capstone Therapeutics | $48.11 million | 0.08 | -$21.23 million | ($3.35) | -0.05 |
| Mitsui & Co. | $92.97 billion | 1.01 | $5.50 billion | $42.41 | 15.52 |
Mitsui & Co. has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Mitsui & Co., indicating that it is currently the more affordable of the two stocks.
Summary
Mitsui & Co. beats Capstone Therapeutics on 10 of the 12 factors compared between the two stocks.
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
About Mitsui & Co.
Mitsui & Co., Ltd. operates as an trading and investment company worldwide. The company engages in the manufacture and sale of steel products; steel processing, maintenance, and recycling activities; investment, development, and trading of mineral and metal resources, as well as resource recycling and industrial developing solutions; and upstream development, logistics, and trading of energy resources, such as natural gas/LNG, oil, coal, and uranium. It also offers power, gas, water, rail, and logistics systems; sales, financing, lease, transportation, and logistics services; and invests in plants, offshore energy development, ships, aviation, space, railways, and automotives, as well as machinery for mining, construction, and industrial use. In addition, the company provides basic chemicals and inorganic raw materials, functional materials, electronic materials, specialty chemicals, housing and lifestyle materials, agri-inputs, animal/human nutrition, and health products; and logistics infrastructures services, including tank terminal operation, as well as plastic recycling and next-generation energy, such as hydrogen and ammonia and forest resources businesses. Further, it engages in the food resources and products, merchandising, retail, fashion and textiles, wellness, healthcare, pharma, hospitality, and human capital businesses. Additionally, it is involved in the ICT, finance, real estate, and logistics businesses. The company was incorporated in 1947 and is headquartered in Tokyo, Japan. Mitsui E&P Italia B operates as a subsidiary of Mitsui & Co., Ltd.
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
